# MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer

> **NCT01240928** · PHASE1 · WITHDRAWN · sponsor: **Vanderbilt-Ingram Cancer Center**

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** MSK-2206
- **DRUG:** Exemestane
- **DRUG:** Goserelin

## Key facts

- **NCT ID:** NCT01240928
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding not available, study did not open to accrual and will not open in future
- **Last updated:** 2013-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01240928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01240928, "MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01240928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*